Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...7778798081828384858687...401402»
  • ||||||||||  SARCOPENIA AT INITIAL DIAGNOSIS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (Bellagio Ballroom - Bellagio Las Vegas) -  Dec 24, 2023 - Abstract #CCCongress2024CCCongress_339;    
    In a subgroup analysis, UC patients were significantly different from CD patients on all four measures, suggesting a higher rate of sarcopenia in CD patients at diagnosis. We plan to expand analysis to compare sarcopenia with disease location, medical therapy, hospitalization rate, need for surgical intervention, and anthropometrics over time.
  • ||||||||||  PREVALENCE OF FRAILTY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A PILOT STUDY. (Bellagio Ballroom - Bellagio Las Vegas) -  Dec 24, 2023 - Abstract #CCCongress2024CCCongress_244;    
    Contrary to what might be assumed, frailty turned out to be a condition independent of the type of IBD, time of evolution, activity and treatment, mostly associated with female sex and a worse quality of life. New studies are required to determine factors predisposing to frailty in IBD patients and prevent its appearance in order to improve their prognosis.
  • ||||||||||  Journal:  Impact of Altered Body Composition on Clinical and Oncological Outcomes in Intrahepatic Cholangiocarcinoma. (Pubmed Central) -  Dec 23, 2023   
    Further, the subgroup analysis revealed a notable effect in the subset of R0-resected patients (myosteatosis vs. non-myosteatosis, 18 vs. 32 months, p = 0.025) and patients with nodal metastases (myosteatosis vs. non-myosteatosis, 7 vs. 18 months, p = 0.016). While altered BC is not associated with perioperative outcomes in iCCA, myosteatosis emerges as a prognostic factor for reduced OS in the overall and sub-populations of resected patients.
  • ||||||||||  Journal:  Frailty in Traumatic Brain Injury-The Significance of Temporal Muscle Thickness. (Pubmed Central) -  Dec 23, 2023   
    High TMT was robustly associated with head trauma sequelae but was also associated with good clinical outcomes in TBI patients. These findings consolidate the significance of TMT as an objective marker of frailty in TBI patients; such measurements may ultimately be leveraged as prognostic indicators.
  • ||||||||||  Review, Journal:  The Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity. (Pubmed Central) -  Dec 23, 2023   
    The aim of this narrative review was to describe the various pathophysiological mechanisms, such as protein synthesis, mitochondrial function, inflammatory response, and the hypothalamic-pituitary-adrenal axis, which are regulated by exercise and contribute to the management of sarcopenia and sarcopenic obesity. Moreover, myokines, factors produced by and released from exercising muscles, are being discussed as they appear to play an important role in mediating the beneficial effects of exercise against sarcopenia.
  • ||||||||||  Review, Journal:  Personalized Physical Activity Programs for the Management of Knee Osteoarthritis in Individuals with Obesity: A Patient-Centered Approach. (Pubmed Central) -  Dec 22, 2023   
    Phase II adopts a patient-centered approach in implementing a PA program that combines an active lifestyle (>6000 steps/day) with land- or water-based exercise programs performed over eight to twelve weeks, with a frequency of three to five sessions per week, each lasting 60 min. In phase III, several strategies can be used to increase the patients' adherence to higher levels of PA, including the following: (i) personalizing PA goal-setting and real-time monitoring; (ii) enhancing physical fitness and the management of sarcopenic obesity; (iii) building a sustainable environment and a supportive social network for an active lifestyle; and (iv) reducing pain, which can ameliorate the clinical severity of KOA and help with weight management in this population.
  • ||||||||||  Journal:  Association between Sarcopenia and Poor Glycemic Control in Older Adults with Type 2 Diabetes Mellitus. (Pubmed Central) -  Dec 22, 2023   
    In phase III, several strategies can be used to increase the patients' adherence to higher levels of PA, including the following: (i) personalizing PA goal-setting and real-time monitoring; (ii) enhancing physical fitness and the management of sarcopenic obesity; (iii) building a sustainable environment and a supportive social network for an active lifestyle; and (iv) reducing pain, which can ameliorate the clinical severity of KOA and help with weight management in this population. Poor glycemic control is associated with the presence of sarcopenia and low muscle mass, which highlights the need to implement better treatment strategies in order to reduce the loss of muscle mass.
  • ||||||||||  Journal:  Causal Roles of Lifestyle, Psychosocial Characteristics and Sleep Status in Sarcopenia: A Mendelian Randomization Study. (Pubmed Central) -  Dec 22, 2023   
    Associations with age and function suggest utility for distinguishing a wide range of vigor and vulnerability in relatively well-functioning older adults. Our results strongly support that coffee intake, education years, smoking, leisure screen time, and moderate-to-vigorous intensity physical activity during leisure time played significantly causal roles in sarcopenia, which may provide new intervention strategies for preventing the development of sarcopenia.
  • ||||||||||  Journal:  lncRNA GPRC5D-AS1 as a ceRNA inhibits skeletal muscle aging by regulating miR-520d-5p. (Pubmed Central) -  Dec 21, 2023   
    As a result, GPRC5D-AS1 functions as a ceRNA of miR-520d-5p to repress cell apoptosis and regulate the expression of muscle regulatory factors, including MyoD, MyoG, Mef2c and Myf5, thus accelerating myoblast proliferation and differentiation, facilitating development of skeletal muscle. In conclusion, lncRNA GPRC5D-AS1 could be a novel therapeutic target for treating sarcopenia.
  • ||||||||||  liproxstatin-1 / Jilin University
    Journal:  Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy. (Pubmed Central) -  Dec 21, 2023   
    Transcriptomic analysis revealed 203 differentially expressed genes in denervated muscle from vehicle or liproxstatin-1 treated mice, including ER stress, nitric oxide signaling, G?i signaling, glucocorticoid receptor signaling, and other pathways. Overall, these data suggest lipid hydroperoxides and oxylipins are key drivers of increased protein breakdown and muscle loss associated with denervation induced atrophy and a potential target for sarcopenia intervention.
  • ||||||||||  Q&A (HALL H) -  Dec 19, 2023 - Abstract #ATTD2024ATTD_281;    
  • ||||||||||  Review, Journal:  Diagnosis and prevalence of cachexia in Asians: A scoping review. (Pubmed Central) -  Dec 19, 2023   
    Several diagnostic criteria, such as BMI and muscle mass, have been used, which are affected by racial differences in body size. However, few studies have used cutoff values for Asians.
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Pennisetum Purpureum in Sarcopenia Patients (clinicaltrials.gov) -  Dec 19, 2023   
    P=N/A,  N=40, Recruiting, 
    Based on a population from central China, the correlated indicators obtained at the L1 level from routine chest CT scans may serve as effective surrogate markers for those at the L3 level in assessing overall skeletal muscle mass. Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Mar 2024 | Initiation date: Sep 2023 --> Jun 2023 | Trial primary completion date: Nov 2023 --> Mar 2024
  • ||||||||||  Enrollment open:  The Sarcopenia Study (clinicaltrials.gov) -  Dec 19, 2023   
    P=N/A,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Mar 2024 | Initiation date: Sep 2023 --> Jun 2023 | Trial primary completion date: Nov 2023 --> Mar 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion, Trial completion date:  Identifying Therapeutic Targets of Accelerated Sarcopenia (clinicaltrials.gov) -  Dec 19, 2023   
    P=N/A,  N=95, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2023
  • ||||||||||  Journal:  Pediatric sarcopenia: An imperfect science in evolution. (Pubmed Central) -  Dec 19, 2023   
    Thus, it is important to understand the mechanisms that underlie the tissue-dependent 3D mitochondrial phenotypic changes that occur in aging and the evolutionary conservation of these mechanisms between Drosophila and mammals. No abstract available
  • ||||||||||  Journal:  AN IN-DEPTH ASSESSMENT OF THE TUMOR'S IMPACT ON SARCOPENIA. (Pubmed Central) -  Dec 18, 2023   
    This article highlights particular mechanisms by which these tumor-derived substances affect the development of muscle loss, including inflammatory processes, metabolic disturbance, proteolysis, and autophagy. The discovery of such targets offers hope for the creation of efficient treatment strategies that can enhance the long-term outlook and quality of life of cancer sufferers who are experiencing muscle loss.
  • ||||||||||  Biomarker, Review, Journal:  Molecular Mechanisms and the Interplay of Important Chronic Obstructive Pulmonary Disease Biomarkers Reveals Novel Therapeutic Targets. (Pubmed Central) -  Dec 18, 2023   
    Excessive ROS production can overwhelm cellular antioxidant systems and act as signaling molecules that regulate cellular processes, including antioxidant defense mechanisms involving glutathione and sirtuins which further leads to cellular apoptosis, cellular senescence, inflammation, and sarcopenia. In this review paper, we focused on COPD from different perspectives including potential markers and different cellular processes such as apoptosis, cellular senescence, inflammation, sirtuins, and sarcopenia, and tried to connect the dots between them so that novel therapeutic strategies to evaluate and target the possible underlying mechanisms in COPD could be explored.
  • ||||||||||  Review, Journal:  Male Osteoporosis and Frailty. (Pubmed Central) -  Dec 18, 2023   
    It is defined as age-related atrophy of skeletal muscle mass that reduces muscle strength, function, and quality of life. This chapter discusses the various aspects of the disease process in the males including its classification, clinical features, diagnosis and treatment.
  • ||||||||||  Review, Journal:  Sarcopenia and Osteoporosis. (Pubmed Central) -  Dec 18, 2023   
    Medications, exercise, and nutrition can promote bone and muscle health. This chapter aims to explore the recent concepts by elucidating the complex relationship between osteoporosis and sarcopenia and advocating for integrated care paradigms.
  • ||||||||||  Review, Journal:  Osteoporosis in Asthma and COPD. (Pubmed Central) -  Dec 18, 2023   
    The presence of osteoporosis in patients with asthma and COPD is invariably asymptomatic unless complicated by fragility fractures, therefore, it is necessary to explore the pathogenesis of osteoporosis in asthma and COPD and special attention is to be paid for early recognition of patients at high risk for osteoporosis in these patients. This chapter is focussed on osteoporosis as an extrapulmonary manifestation of asthma and COPD with an emphasis on the pathogenesis, risk factor, potential mechanism of osteoporosis, diagnosis, and prevention with passing reference to treatment as well in asthma and COPD patients.
  • ||||||||||  Review, Journal:  Osteoporosis and Obesity. (Pubmed Central) -  Dec 18, 2023   
    Physicians should keep a comprehensive approach to treating obese patients with osteoporosis, including lifestyle modifications, weight management, fall prevention strategies, and pharmacological interventions. Further research is needed to better understand the relationship between obesity and bone health.